Jazz Pharmaceuticals’ acquisition of Chimerix brings a drug that could become the first approved therapy for a rare and ...
OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will ...
Blood-Brain Barrier Technology ... In conclusion, Alector’s presentation at the TD Cowen Conference underscored its commitment to advancing therapies for neurodegenerative diseases.
A surgeon examining a patient's brain in an operating room ... On February 3rd, TD Cowen increased Boston Scientific Corporation’s (NYSE:BSX) target price to $115 from $110 and reiterated ...
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...
Brain cancers are notoriously difficult to treat ... speaking during the company’s presentation Wednesday at TD Cowen’s annual healthcare conference in Boston. “I’m a pediatric oncologist ...
KOL Event on aneurysmal Subarachnoid Hemorrhage (aSAH) ...
Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and ...